Clinical outcomes of uterine sarcomas: Results from 14 years worth of experience in the Kinki district in Japan (1990-2003)

International Journal of Gynecological Cancer

Volumn 16, Issue 3, 2006, Pages 1358-1363

  Kokawa, K ^a   Nishiyama, K ^b   Ikeuchi, M ^c   Ihara, Y ^d   Akamatsu, N ^e   Enomoto, T ^f   Ishiko, O ^g   Motoyama, S ^h   Fujii, S ⁱ   Umesaki, N ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c JAPANESE RED CROSS WAKAYAMA MEDICAL CENTER   (Japan)

^d KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^e HIMEJI RED CROSS HOSPITAL   (Japan)

^f OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^g OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ KYOTO SECOND RED CROSS HOSPITAL   (Japan)

Author keywords

Incidence; Japan; Survival; Treatment; Uterine sarcomas

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOSARCOMA; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; ENDOMETRIUM SARCOMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; JAPAN; LEIOMYOSARCOMA; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; UTERUS SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYSTERECTOMY; JAPAN; LYMPH NODE EXCISION; MIDDLE AGED; RETROSPECTIVE STUDIES; SARCOMA; SURVIVAL RATE; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 33745084836     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00536.x     Document Type: Article

References (24)

1. Nordal R Thoresen S. Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality. Eur J Cancer 1997 33: 907 11.
2. Giuntoli II. RL Metzinger DS DiMarco CS et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 2003 89: 460 9.
3. Gadducci A Sartoti E Landoni F et al. Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol 1996 63: 247 53.
4. Curtin JP Blessing JA Soper JT DeGeest K. Paclitaxel in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2001 83: 268 70.
5. Harlow B Weiss N Lofton S. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 1986 67: 399 402.
6. Platz C Benda J. Female genital tract cancer. Cancer 1995 75: 270 94.
7. Brooks SE Zhan M Cote T Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol 2004 93: 204 8.
8. Major FJ Blessing JA Silverberg SG et al. Prognostic factors in early-stage uterine sarcoma: a Gynecologic Oncology Group study. Cancer 1993 71: 1702 9.
9. Brechuck A Rubin SC Hoskins WJ Saigo PE Pierce VK Lewis JL. Treatment of endometrial stromal tumors. Gynecol Oncol 1990 36: 60 5.
10. Omura GA Blessing JA Major F et al. A randomized clinical trail of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 1988 38: 233 9.
11. Sutton G Blessing JA Malfetano JH. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 1996 62: 226 9.
12. Sutton GP Brunetto V Kilgore L et al. A phase III trial of ifosmaide with without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 2000 79: 147 53.
13. Jl Currie Blessing JA McGehee R Soper JT Berman M. Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 1996 61: 94 6.
14. Fujita H Adachi S Kigawa J Sugiyama T Takeuchi S. A clinicopathological study of uterine sarcoma in last decade - a retrospective study of KCOG/USSG inter group study. Adv Obstet Gynecol 2004 56: 463 5.
15. Sagae S Yamashita K Ishioka S et al. Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology 2004 67: 33 9.
16. Oda K Okada S Nei T et al. Cytodiagnostic problems in uterine sarcoma. Analysis according to a novel classification of tumor growth types. Acta Cytol 2004 48: 181 6.
17. Sahdev A Sohaib SA Shepherd JH Oram DH Reznek RH. MR imaging of uterine sarcoma. AJR 2001 177: 1307 11.
18. Reed NS. Uterine sarcomas - the biggest challenge? Clin Oncol 2002 14: 50 3.
19. Yamada SD Burger RA Brewster WR Anton D Kohler MF Monk BJ. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 2000 88: 2782 6.
20. Goff BA Rice LW Fleischhacker D Muntz HG Falkenberry SS Nikrui N. Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and site of recurrence. Gynecol Oncol 1993 50: 105 9.
21. Dinh TA Oliva EA Fuller AF Jr. Lee H Goodman A. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecol Oncol 2004 92: 648 52.
22. Toyoshima M Nakahara J Mustang G et al. Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. Gynecol Oncol 2004 94: 774 8.
23. Hensley ML Maki R Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002 20: 2824 31.
24. Lei KM Ostruszka LJ Shewach D et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004 22: 1706 12.